Bloomberg – Kyle Bass is expanding his campaign against pharmaceutical companies.
Shire Plc is the newest target of the hedge fund manager’s strategy to challenge drug patents, according to filings last week with the U.S. Patent and Trademark Office. Bass is challenging patents on Lialda and Gattex, according to the filings, which together made up 12 percent of Shire’s 2014 revenue.
Shire, ‘Three’s Company,’ Seeds: Intellectual Property
This entry was posted in Syndicated. Bookmark the permalink.
